PET Using Prostate-Specific Ligand Accurately Localizes Recurrent Prostate Cancer


PET using a gallium-labeled prostate-specific membrane antigen (68Ga-PSMA-11) as ligand accurately localizes recurrent prostate cancer

In retrospective research, 68Ga-PSMA-11 has provided unprecedented accuracy for localizing recurrent prostate cancer, Dr. Thomas A. Hope of the University of California, San Francisco, and colleagues note in JAMA Oncology, online March 28.

In their prospective study of 635 men with biochemically recurrent prostate cancer, the team found an overall PET detection rate of 75%, with significant increases in detection rate with increasing prostate-specific antigen (PSA) levels: 38% for <0.5 ng/mL, 57% for 0.5 to <1.0 ng/mL, 84% for 1.0 to <2.0 ng/mL, 86% for 2.0 to <5.0 ng and 97% for 5.0 ng/mL or higher.

The positive predictive value of 68Ga-PSMA-11 PET was 92%, and the sensitivity was 92% on a per-patient basis and 90% on a per-region basis.

Only 2% of patients experienced grade-1 events after the PET scan, none of them requiring intervention, and there were no grade-2 or higher events.

68Ga-PSMA-11 PET provides early detection of metastases and contributes highly relevant information in a biochemical recurrence setting,


Wolfgang P. Fendler et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate CancerA Prospective Single-Arm Clinical Trial  JAMA Oncol. Published online March 28, 2019. doi:10.1001/jamaoncol.2019.0096